Deeper Knowledge, Faster

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Cantor Fitzgerald
US Department of Justice
Federal Trade Commission

Generated: December 13, 2017

DrugPatentWatch Database Preview

Details for Patent: 4,882,452

« Back to Dashboard

Summary for Patent: 4,882,452

Title: Process for the preparation of ifosfamide having improved properties
Abstract:Ifosfamide having improved properties is obtained by crystallization from a solvent mixture selected from the group consisting of (a) a mixture of diethyl ether and a C.sub.1 -C.sub.3 alkanol or (b) a mixture of diisopropyl ether and a C.sub.1 -C.sub.3 alkanol under specific controlled conditions.
Inventor(s): Engel; Jurgen (Alzenau, DE), Muller; Siegfried (Bad Homburg, DE), Laubner; Werner (Halle, DE)
Assignee: Asta Pharma Akteingesellschaft (Frankfurt am Main, DE)
Application Number:07/163,586
Patent Claim Types:
see list of patent claims
Compound; Process; Formulation; Composition;

No matches for this query

Foreign Priority and PCT Information for Patent: 4,882,452

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany3707154Mar 06, 1987

International Patent Family for Patent: 4,882,452

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria63121► Subscribe
Canada1305970► Subscribe
Germany3805329► Subscribe
Germany3862595► Subscribe
Denmark116988► Subscribe
Denmark168822► Subscribe
European Patent Office0281832► Subscribe
Finland86187► Subscribe
Finland881020► Subscribe
Greece3001898► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Daiichi Sankyo
US Department of Justice
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: